Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;61(10):2108-2117.
doi: 10.1007/s00125-018-4670-7. Epub 2018 Aug 22.

SGLT2 Inhibitors and Mechanisms of Cardiovascular Benefit: A State-Of-The-Art Review


SGLT2 Inhibitors and Mechanisms of Cardiovascular Benefit: A State-Of-The-Art Review

Subodh Verma et al. Diabetologia. .


Sodium-glucose cotransporter (SGLT)2 inhibitors have been demonstrated to reduce cardiovascular events, particularly heart failure, in cardiovascular outcome trials. Here, we review the proposed mechanistic underpinnings of this benefit. Specifically, we focus on the role of SGLT2 inhibitors in optimising ventricular loading conditions through their effect on diuresis and natriuresis, in addition to reducing afterload and improving vascular structure and function. Further insights into the role of SGLT2 inhibition in myocardial metabolism and substrate utilisation are outlined. Finally, we discuss two emerging themes: how SGLT2 inhibitors may regulate Na+/H+ exchange at the level of the heart and kidney and how they may modulate adipokine production. The mechanistic discussion is placed in the context of completed and ongoing trials of SGLT2 inhibitors in the prevention and treatment of heart failure in individuals with and without diabetes.

Keywords: Cardiovascular effects; Heart failure; Mechanisms; Review; SGLT2 inhibitors.

Similar articles

See all similar articles

Cited by 50 articles

See all "Cited by" articles


    1. Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2031-41 - PubMed
    1. Cardiovasc Pathol. 2005 Mar-Apr;14(2):49-60 - PubMed
    1. Physiol Rev. 2010 Jan;90(1):207-58 - PubMed
    1. Diabetologia. 2012 Aug;55(8):2154-62 - PubMed
    1. Diabetes Obes Metab. 2013 Jul;15(7):613-21 - PubMed

Publication types

MeSH terms

LinkOut - more resources